Payden & Rygel’s MetLife MET Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.77M | Hold |
95,700
| – | – | 0.52% | 70 |
|
|
2025
Q4 | $7.55M | Sell |
95,700
-2,500
| -3% | -$198K | 0.52% | 66 |
|
|
2025
Q3 | $8.09M | Sell |
98,200
-74,200
| -43% | -$5.84M | 0.67% | 61 |
|
|
2025
Q2 | $13.9M | Hold |
172,400
| – | – | 1.15% | 40 |
|
|
2025
Q1 | $13.8M | Hold |
172,400
| – | – | 1.19% | 38 |
|
|
2024
Q4 | $14.1M | Sell |
172,400
-168,500
| -49% | -$14M | 1.22% | 40 |
|
|
2024
Q3 | $28.1M | Buy |
340,900
+67,400
| +25% | +$5.03M | 2.17% | 7 |
|
|
2024
Q2 | $19.2M | Sell |
273,500
-22,100
| -7% | -$1.58M | 1.55% | 26 |
|
|
2024
Q1 | $21.9M | Buy |
295,600
+1,300
| +0.4% | +$90.6K | 1.03% | 23 |
|
|
2023
Q4 | $19.5M | Buy |
294,300
+46,000
| +19% | +$2.88M | 1.35% | 25 |
|
|
2023
Q3 | $15.6M | Buy |
+248,300
| New | +$15.5M | 1.07% | 32 |
|
|
2023
Q2 | – | Sell |
-240
| Closed | -$14K | – | 138 |
|
|
2023
Q1 | $14K | Sell |
240
-484,400
| -100% | -$32.7M | ﹤0.01% | 122 |
|
|
2022
Q4 | $35.1M | Hold |
484,640
| – | – | 1.87% | 11 |
|
|
2022
Q3 | $29.5M | Buy |
484,640
+9,500
| +2% | +$607K | 1.72% | 18 |
|
|
2022
Q2 | $29.8M | Sell |
475,140
-15,400
| -3% | -$1.02M | 1.79% | 15 |
|
|
2022
Q1 | $34.5M | Buy |
490,540
+147,200
| +43% | +$9.95M | 1.74% | 19 |
|
|
2021
Q4 | $21.5M | Buy |
+343,340
| New | +$21.5M | 0.99% | 57 |
|
|
2020
Q1 | – | Sell |
-5,300
| Closed | -$270K | – | 124 |
|
|
2019
Q4 | $270K | Hold |
5,300
| – | – | 0.02% | 81 |
|
|
2019
Q3 | $250K | Sell |
5,300
-297,700
| -98% | -$14.2M | 0.02% | 77 |
|
|
2019
Q2 | $15.1M | Hold |
303,000
| – | – | 1.03% | 54 |
|
|
2019
Q1 | $12.9M | Hold |
303,000
| – | – | 0.94% | 57 |
|
|
2018
Q4 | $12.4M | Buy |
+303,000
| New | +$13M | 1% | 53 |
|
|
2016
Q3 | – | Sell |
-218,005
| Closed | -$7.74M | – | 113 |
|
|
2016
Q2 | $7.74M | Sell |
218,005
-308
| -0.1% | -$12K | 0.88% | 58 |
|
|
2016
Q1 | $8.55M | Buy |
218,313
+224
| +0.1% | +$8.37K | 1.04% | 50 |
|
|
2015
Q4 | $9.37M | Buy |
218,089
+870
| +0.4% | +$38.3K | 1.24% | 38 |
|
|
2015
Q3 | $9.13M | Buy |
217,219
+34,109
| +19% | +$1.59M | 1.31% | 37 |
|
|
2015
Q2 | $9.14M | Sell |
183,110
-1,459
| -0.8% | -$69.1K | 1.21% | 43 |
|
|
2015
Q1 | $8.31M | Buy |
+184,569
| New | +$8.29M | 1.08% | 51 |
|
Other funds holding MET
VCM
VPM
Payden & Rygel's MET Position: Q1 2026 in Review
Payden & Rygel held its MetLife (MET) position steady in Q1 2026 at 95,700 shares worth $6.77M. The position accounts for 0.52% of the portfolio, ranked #70.
Payden & Rygel first reported a position in MET in Q1 2015 and has held it in 28 quarters since. The position peaked at $35.1M in Q4 2022. 1,371 funds tracked by Wall St. Rank hold MET as of Q1 2026.
- Payden & Rygel held 95,700 shares of MetLife worth $6.77M as of Q1 2026.
- Payden & Rygel left its MetLife share count unchanged in Q1 2026.
- MetLife made up 0.52% of Payden & Rygel's portfolio in Q1 2026, its #70 holding.
- Payden & Rygel first reported a position in MetLife in Q1 2015 and has held it in 28 quarters since.
- Payden & Rygel's MetLife position peaked at $35.1M in Q4 2022.
- 1,371 funds tracked by Wall St. Rank held MetLife as of Q1 2026.
Based on Payden & Rygel's 13F filing for Q1 2026, filed 12 May 2026.